To the top

Page Manager: Webmaster
Last update: 4/19/2017 1:56 PM

Tell a friend about this page
Print version

Pierre Åman - University of Gothenburg, Sweden Till startsida
Sitemap
To content Read more about how we use cookies on gu.se

Pierre Åman

Professor

Pierre Åman
Professor
pierre.aman@llcr.med.gu.se
+46 31 786 6732
0706-846085

Postal Address: Box 425, 40530 Göteborg
Visiting Address: Medicinaregata 1F , 41390 Göteborg


Department of Laboratory Medicine at Institute of Biomedicine (More Information)
Sahlgrenska universitetssjukhuset
413 45 Göteborg
Visiting Address: Gula stråket 8 , 413 45 Göteborg

Latest publications

JAK–STAT signalling controls cancer stem cell properties including chemotherapy resistance in myxoid liposarcoma
Soheila Dolatabadi, Emma Jonasson, Malin Lindén, Bentolhoda Fereydouni, Karin Bäcksten et al.
International Journal of Cancer, Journal article 2019
Journal article

Requirement for YAP1 signaling in myxoid liposarcoma.
Marcel Trautmann, Ya-Yun Cheng, Patrizia Jensen, Ninel Azoitei, Ines Brunner et al.
EMBO molecular medicine, Journal article 2019
Journal article

FET family fusion oncoproteins target the SWI/SNF chromatin remodeling complex
Malin Lindén, Christer Thomsen, Pernilla Grundevik, Emma Jonasson, Daniel Andersson et al.
EMBO Reports, Journal article 2019
Journal article

Phosphatidylinositol-3-kinase (PI3K)/Akt Signaling is Functionally Essential in Myxoid Liposarcoma
M. Trautmann, M. Cyra, I. Isfort, B. Jeiler, A. Kruger et al.
Molecular Cancer Therapeutics, Journal article 2019
Journal article

Identification of inhibitors regulating cell proliferation and FUS-DDIT3 expression in myxoid liposarcoma using combined DNA, mRNA, and protein analyses.
David Svec, Soheila Dolatabadi, Christer Thomsen, Nicole Cordes, Mark Shannon et al.
Laboratory investigation; a journal of technical methods and pathology, Journal article 2018
Journal article

FUS-DDIT3 Fusion Protein-Driven IGF-IR Signaling is a Therapeutic Target in Myxoid Liposarcoma
M. Trautmann, J. Menzel, C. Bertling, M. Cyra, I. Isfort et al.
Clinical Cancer Research, Journal article 2017
Journal article

HR23b expression is a potential predictive biomarker for HDAC inhibitor treatment in mesenchymal tumours and is associated with response to vorinostat.
Michaela Angelika Ihle, Sabine Merkelbach-Bruse, Wolfgang Hartmann, Sebastian Bauer, Nancy Ratner et al.
The journal of pathology. Clinical research, Journal article 2016
Journal article

Showing 41 - 50 of 53

2005

Cell-type-specific expression of p53 and p21 in giant cell arteritis.
Claes Nordborg, Pierre Åman, M Persson, Elisabeth Nordborg
APMIS : acta pathologica, microbiologica, et immunologica Scandinavica, Journal article 2005
Journal article

Fusion oncogenes in tumor development.
Pierre Åman
Seminars in cancer biology, Review article 2005
Review article

Functional studies of fusion oncogenes associated with the EWS family of sarcomas
Mattias K Andersson, Anita Olofsson, Pierre Åman
Cancer and Development, Fairmont Banff Springs, Banff, Alberta, Canada, Poster 2005
Poster

Skadade stamceller ger cancer hos unga
Mattias K Andersson, Pierre Åman
Forskning & Framsteg, Magazine article 2005
Magazine article

Fusion oncogenes.
Pierre Åman
Seminars in cancer biology, Chapter in book 2005
Chapter in book

Quantitative real-time PCR for cancer detection: the lymphoma case.
Anders Ståhlberg, Neven Zoric, Pierre Åman, Mikael Kubista
Expert review of molecular diagnostics, Review article 2005
Review article

Oncostatin M signaling in human glioma cell lines.
Annika Krona, Sofia Järnum, Leif G Salford, Bengt Widegren, Pierre Åman
Oncology reports, Journal article 2005
Journal article

2004

Translocated in liposarcoma (TLS) is a substrate for fibroblast growth factor receptor-1.
Peter Klint, Ulf Hellman, Christer Wernstedt, Pierre Åman, David Ron et al.
Cellular signalling, Journal article 2004
Journal article

Showing 41 - 50 of 53

Page Manager: Webmaster|Last update: 4/19/2017
Share:

The University of Gothenburg uses cookies to provide you with the best possible user experience. By continuing on this website, you approve of our use of cookies.  What are cookies?